Clinical Trial Vendor Selection: Capability, Not Price

At a glance

• Vendor selection is the first act of oversight, not a procurement event: the RFP and evaluation you choose with become the evidence an inspector reads later.
• The regulation makes selection a sponsor responsibility: you must assess a provider’s suitability and select one that can actually do the transferred work.
• Choose for documented capability and a fit-for-purpose quality system, not for the lowest bid or the fastest timeline.
• Weight selection criteria to what is critical to the quality of your trial, and write down why you chose who you chose.
• A clean selection record (requirements, proposals, evaluation, justification) is what makes the rest of the vendor relationship defensible.

This is the opening stage of vendor management in clinical trials, and it sets up everything in vendor oversight that follows.

Selection is the first act of oversight

It is tempting to treat vendor selection as procurement: gather quotes, compare price and timeline, pick a winner, move on. In a regulated trial that framing is a trap, because selection is where your oversight obligation begins, not where it is deferred.

ICH E6(R3) is explicit. The sponsor is responsible for assessing the suitability of, and selecting, the service provider to ensure they can adequately undertake the activities being transferred to them. That is a quality decision, not a purchasing one. The same guideline lists the selection and oversight of service providers as fundamental features of the oversight process, which means a weak selection is not a clean slate you can fix later with monitoring. It is a hole you spend the rest of the trial trying to backfill.

There is also a documentary reason to take selection seriously. Regulators expect a sponsor to be able to justify how and why a particular provider was chosen. The artifacts you generate while selecting, the requirements, the proposals received, the evaluation, and the rationale for the decision, are the first entries in that vendor’s oversight record. Treat them as evidence from the start and they will hold up; treat them as throwaway procurement paperwork and you will be reconstructing them under pressure.

Define what “good” means before you look at vendors

The most common selection mistake is comparing vendors before deciding what you actually need from them. The fix comes from ICH E8(R1): identify the factors critical to quality for your specific trial first, then let those factors drive the criteria. A trial whose primary endpoint depends on central imaging has different critical factors than one that lives or dies on patient retention. E8 frames this as focusing effort on the activities that are essential to the study, and the same discipline applies to choosing who performs them.

In practice, that means writing your selection criteria as a weighted set tied to your critical-to-quality factors, before the demos start. Capability against those factors, relevant therapeutic and operational experience, and the strength of the provider’s quality system should carry the most weight. Price and timeline matter, but they are constraints to satisfy, not the criteria that should decide a close call.

Selection rigor should itself be proportionate. A full competitive process with multiple rounds is right for a CRO that will run your pivotal trial; it is overkill for a low-risk courier, where a documented choice against basic criteria is enough. The risk-based logic that governs oversight applies just as much to how hard you select. Spending equal selection effort on every vendor is a reliable way to under-resource the few choices that actually decide the trial.

What to evaluate

A capability-first evaluation looks at a few things the sales deck will not volunteer:

• A fit-for-purpose quality system. You are not just buying a service, you are relying on the provider’s processes. ICH E6(R3) recognises that a service provider’s activities may be performed under its existing quality management processes, even ones not designed specifically for GCP, provided they are fit for purpose in the context of the trial. So the question is not “do you have SOPs?” but “do your processes actually cover the risks of the work I am giving you?”
• Access to the information you will need to oversee them. ICH E6(R3) expects the sponsor to have access to relevant information, such as SOPs and performance metrics, for the selection and oversight of service providers. A provider that resists sharing how it works during selection will resist during oversight. Treat transparency now as a leading indicator.
• Demonstrated capability, not asserted capability. Past performance on comparable trials, references, and evidence of the specific capability your critical factors require. Capability claims that cannot be evidenced are marketing.
• Financial and operational stability. A provider that is financially shaky may cut staffing or be acquired mid-trial, which is an oversight risk even when the technical capability is strong.
• Capacity and the people actually assigned. A provider with the right capability on paper but no senior staff free for your study is a different proposition than the org chart suggests. Ask who will be assigned, and confirm it holds during qualification.

Run the process so it produces evidence

The mechanics of selection, an RFI to scope the field, an RFP or qualification questionnaire to evaluate, and a structured scoring matrix, exist to do two jobs: make a good decision, and leave a record that the decision was sound. Score every shortlisted vendor against the same weighted criteria. Capture the evaluation in a matrix rather than a hallway consensus. Write a short selection rationale that says, in plain terms, why the chosen provider best fits the trial’s critical factors.

A useful habit is to fix the scoring scale and the weightings before any proposal is opened, so the evaluation cannot quietly drift to fit a favoured vendor. When two providers score closely, the tie-breaker should be their fit against the critical-to-quality factors, not the price line.

This record is not bureaucracy. It is the document that answers an inspector’s “why this CRO?” without anyone having to remember a decision made eighteen months earlier. It is also the bridge into the next stage: a strong selection package feeds directly into qualification, where you confirm with evidence what selection assessed on paper.

Direct award or competitive RFP?

Not every selection needs a competition. A direct award, choosing a known provider without a formal RFP, is legitimate when the work is low-risk, when you hold current performance evidence for that provider, or when a genuine sole source exists. What matters is not the route but the record: a direct award still needs documented criteria, a suitability assessment, and a written rationale, because the regulator’s question (“why this provider?”) is the same either way. A competitive RFP earns its overhead when the work is critical, the field is genuinely open, or you need comparative evidence to defend the choice. Match the process to the stakes, and document whichever one you run.

Selection is not qualification (and not contracting)

Keep three stages distinct so none of them gets skipped. Selection chooses the provider. Qualification confirms, with evidence and to a depth set by risk, that the chosen provider meets your standards. Contracting writes down exactly which obligations transfer, which is what actually moves accountability under the regulations. Teams that blur selection into a single “onboarding” step tend to lose the qualification evidence and the contractual precision, and both gaps surface at inspection. Selection earns the provider a place; the stages after it are how you make the relationship real and demonstrable.

Where selection goes wrong

• Price-led decisions. The lowest bid that cannot evidence capability against your critical factors is the most expensive choice you can make, paid later in oversight effort and findings.
• No defined criteria. Evaluating vendors without weighted, pre-agreed criteria means the decision is driven by whoever demos best, not by fit.
• Selection theatre. Running an RFP whose outcome was decided in advance produces a record that does not match reality, which is worse than a thin record that does.
• No paper trail. A sound decision with no documented rationale is indistinguishable, at inspection, from no decision at all.

How VendorVigilance helps here. Selection done well is structured and evidenced, and that is exactly what VendorVigilance’s Selections module is built for: template-driven evaluation workflows from direct awards to competitive RFPs, with standardised scoring and analysis, drawing on a central vendor registry so the decision is informed by each provider’s existing qualification status, performance history, and risk context. The output is not just a chosen vendor; it is a selection record that already lives in the same system as the oversight that follows. Explore the product.

The bottom line

Choose vendors the way you will have to defend the choice: against the factors critical to your trial’s quality, on evidenced capability and a fit-for-purpose quality system, with the reasoning written down. Price and timeline are real constraints, but they are not the decision. Get selection right and qualification, contracting, and oversight all start from solid ground. Get it wrong and you spend the trial managing a provider you should not have picked.

Sources

• ICH E6(R3) Good Clinical Practice (R3)
• ICH E8(R1) General Considerations for Clinical Studies (R1)